{"url_path":"/sec/allr/8-k/2026-06-22/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-22","source_url":"https://www.sec.gov/Archives/edgar/data/1860657/0001213900-26-070382-index.html","accession_number":"0001213900-26-070382","cik":"0001860657","ticker":"ALLR","issuer_name":"Allarity Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1860657/0001213900-26-070382-index.html","primary_entity_key":"0001860657","primary_entity_name":"Allarity Therapeutics, Inc."},"word_count":311,"has_tables":true,"body_markdown":"false\n0001860657\n\n0001860657\n\n2026-06-18\n2026-06-18\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n**FORM 8-K**\n\n \n\n**CURRENT REPORT**\n\n**Pursuant to Section 13 OR 15(d) of The Securities\nExchange Act of 1934**\n\n \n\nDate of Report (Date of earliest event reported)\n**June 18, 2026**\n\n \n\n**ALLARITY THERAPEUTICS, INC.**\n\n(Exact name of registrant as specified in its charter)\n\n \n\n**Delaware**\n \n**001-41160**\n \n**87-2147982**\n\n(State or other jurisdiction\n\nof incorporation)\n \n(Commission File Number)\n \n(IRS Employer\n\nIdentification No.)\n\n \n\n**123 E Tarpon Ave,**\n\n**Tarpon Springs, FL 34689**\n\n(Address of principal executive offices)\n\n \n\n**(401) 426-4664**\n\n(Registrant’s telephone number, including\narea code)\n\n \n\n**Not applicable**\n\n(Former name or former address, if changed since\nlast report)\n\n \n\nCheck the appropriate box below if the Form 8-K\nfiling is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:\n\n \n\n☐\nWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n☐\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n\n☐\nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n☐\nPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities registered pursuant to Section 12(b)\nof the Act:\n\n \n\n**Title of each class**\n \n**Trading Symbol(s)**\n \n**Name of each exchange on which registered**\n\nCommon Stock, par value $0.0001 per share\n \nALLR\n \nThe Nasdaq Stock Market LLC\n\n \n\nIndicate by check mark whether the registrant\nis an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the\nSecurities Exchange Act of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging growth company ☒\n\n \n\nIf an emerging growth company, indicate by check\nmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting\nstandards provided pursuant to Section 13(a) of the Exchange Act. ☐"}